Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Published Online: 2017-07-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Agnieszka Jagiełło-Gruszfeld•Ahmad Awada•Barbara Pistilli•Bharani Dharan•Carlos L Arteaga•Cristian Massacesi•Emmanuelle Di Tomaso•Hiroji Iwata•Javier Cortés•José Baselga•Ling-Ming Tseng•Mario Campone•Mark Clemons•Masato Takahashi•Michele De Laurentiis•Norikazu Masuda•Patrick Urban•Peter Vuylsteke•Sara Hurvitz•Seock-Ah Im•Soulef Hachemi•Stephen Chia•Walter Jonat•Yoshinori Ito•Zefei Jiang
